Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Sai Life Sciences has made available the recording of its earnings call for the audited financial results of the quarter and year ended March 31, 2026. Investors can access the recording on the company's website.
May 15 2026 19:05:00
Stock Crash: Outperforming contract research firm tanks 14% after Q4 results
Sai Life Sciences' stock experienced a notable decline following its Q4 FY26 earnings release, despite the company's strong performance since its IPO. The market reacted negatively to the reported quarterly results, with the share price falling by approximately 8%.
May 15 2026 10:05:00
Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sai Life Sciences announced audited financial results for FY26, with revenue from operations increasing 29% YoY to Rs.2,192 crore and net profit growing 109% YoY to Rs.355 crore. EBITDA also rose 56% to Rs.661 crore, driven by deepening engagement with large pharma and investments in new technologies.
May 14 2026 23:05:00
Sai Life Sciences Ltd - 544306 - Board Meeting Outcome for Board Meeting Outcome For Approval Of Audited Financial Results For The Financial Year Ending 31.03.2026
Sai Life Sciences' board approved audited Standalone and Cons. Financial Results for Q4 and FY26. For FY26, cons. revenue grew by 29.38% to ₹2,192.49 crores, and net profit increased by 105.07% to ₹348.91 crores. The statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified opinion on the results.
May 14 2026 22:05:00
Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sai Life Sciences announced its Bidar campus (API manufacturing) is now 100% powered by renewable energy. This makes it the first Indian CRDMO site to achieve full green electricity usage, significantly contributing to the company's sustainability goals by avoiding 35,110 tonnes of CO2 annually.
May 11 2026 16:05:00
Sai Life Sciences Ltd - 544306 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sai Life Sciences will host an earnings conference call on May 15, 2026, at 4:00 PM IST to discuss its audited financial results for Q4 FY26 and the full fiscal year. Key management, including the MD & CEO and CFO, will participate.
May 11 2026 11:05:00
Sai Life Sciences Limited
Sai Life Sciences received a regulatory order on April 29, 2026, from the Joint Commissioner of Commercial Taxes, Kalaburagi, demanding INR 32.85 crore. The demand includes IGST, interest, and penalty related to alleged excess input tax credit availment in FY22. The company plans to appeal and does not expect a material financial impact.
Apr 30 2026 08:04:00
Sai Life Sciences Limited
Sai Life Sciences received a regulatory order on April 29, 2026, from the Joint Commissioner of Commercial Taxes, Kalaburagi, demanding INR 32.85 crore. The demand includes IGST, interest, and penalty related to alleged excess input tax credit availment in FY22. The company plans to appeal and does not expect a material financial impact.
Apr 30 2026 08:04:00
Sai Life Sciences Limited
SAI LIFE SCIENCES board to meet on May 14, 2026, to consider and approve audited standalone and consolidated financial results for FY26. The meeting will review the company's full-year performance.
Apr 21 2026 14:04:00
Sai Life Sciences Ltd - 544306 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone & Consolidated) For The Fourth Quarter And Year Ended 31 March 2026.
Sai Life Sciences board to meet on May 14, 2026, to approve audited Q4 and FY26 financial results. The trading window has been closed since April 1, 2026, and will reopen 48 hours after results declaration.
Apr 21 2026 13:04:00
Read More